About Sylvain Doré
Sylvain Doré, PhD, FAHA is a Professor of Anesthesiology, as well as a Professor of Neurology, Psychiatry, Pharmaceutics, and Neuroscience, at the University of Florida, College of Medicine.
Dr. Doré attained his PhD in Biomedical Science from the University of Montreal and an MS degree in Pharmacology at the University of Quebec. He received post-PhD training in Psychiatry at McGill University, as well as post-PhD training in Neuroscience under the supervision of Dr. Solomon H Snyder at Johns Hopkins University.
Dr. Doré’s research pertains to studying new effective mechanisms that limit neuronal dysfunction associated with ischemic and hemorrhagic stroke, traumatic brain injury, Alzheimer disease (AD), aging, and various other neurological disorders. His objective is focused on understanding the protective role of heme metabolites in the brain using cellular/molecular techniques and various models of stroke, Alzheimer disease, and dementia. New knowledge is gained specifically by investigating the action and the role of activity of the heme oxygenase enzyme and its unique bioactive metabolites: carbon monoxide, iron, biliverdin, and bilirubin. He has also conducted pioneered work in the field of pro-inflammatory prostaglandins and the GPRR receptors. His overall goal is to slow down the progression of the disease and ultimately stop it.
Winning the Chairman Award for Outstanding Service and Dedication at the Department of Anesthesiology, University of Florida, is among his many accomplishments. He is involved in many ad hoc journal peer review activities and sits on the editorial board of multiple journals, including Frontiers in Neuroscience, Neurotoxicity Research, Faculty of 1000, World Journal of Cardiology, International Journal of Clinical and Experimental Medicine, Translational Neuroscience, and International Journal of Clinical Anesthesiology.
Dr. Doré is a well-published author with over 160 scholarly publications across 13 different disciplines. He has received many grant awards funding his research and has filed patents for five intellectual properties.
- Acute Ischemic Stroke
- Alzheimer disease
- Cerebral amyloid angiopathy
- Cerebrovascular occlusive disease
- Exchange transfusion
- Hypoxic-Ischemic Encephalopathy (HIE)
- Sickle cell disease
- Subarachnoid hemorrhage
- Traumatic Brain Injury
- Vascular dementia
- Prevention of Brain Injury
- Clinical Translational Neuroscience
- Natural products
- Translational drug development